Downregulation of miR-610 promotes proliferation and tumorigenicity and activates Wnt/β-catenin signaling in human hepatocellular carcinoma by unknown
Zeng et al. Molecular Cancer 2014, 13:261
http://www.molecular-cancer.com/content/13/1/261RESEARCH Open AccessDownregulation of miR-610 promotes
proliferation and tumorigenicity and activates
Wnt/β-catenin signaling in human hepatocellular
carcinoma
Xian-Cheng Zeng1,2,3†, Fo-Qiu Liu4†, Rong Yan4†, Hui-Min Yi3, Tong Zhang3, Guo-Ying Wang3, Yang Li3
and Nan Jiang3*Abstract
Background: Wnt/β-catenin signaling pathway plays important roles in human cancer progression. Better
understanding the mechanism underlying regulation of Wnt/β-catenin signaling pathway might provide novel
therapeutic targets for cancer treatment.
Methods: miR-610 expression levels in hepatocellular carcinoma (HCC) cell lines, HCC tissues and 76 archived HCC
specimens were determined using real-time PCR. Cell viability was measured by 3-[4, 5-dimethylthiazol-2-yl]-2,
5-diphenyltetrazolium bromide (MTT) assay. The level of DNA synthesis was determined by BrdU incorporation
assay. Flow cytometry analysis was used to analyze cell cycle progression. The cells proliferation and tumorigenesis
were determined by colony formation and anchorage-independent growth assays in vitro, and by xenograft tumors
in vivo. Luciferase assay and micro-ribonucleoprotein complex immunoprecipitation assay were used to confirm the
association of the targeted mRNAs with miR-610.
Results: miR-610 was downregulated in human HCC cells and tissues, and correlated with HCC progression and
patient survival. Inhibition of miR-610 promoted, but overexpression of miR-610 reduced, HCC cell proliferation and
tumorigenicity both in vitro and in vivo. Furthermore, we found that inhibiting miR-610 activated, but overexpressing
miR-610 decreased, the Wnt/β-catenin activity through directly suppressing lipoprotein receptor-related protein 6
(LRP6) and transducin β–like protein 1 (TBL1X). The in vitro analysis was consistent with the inverse correlation detected
between miR-610 levels with expression of LRP6 and TBL1X in a cohort of human HCC samples.
Conclusions: Our results indicate that miR-610 downregulation plays essential roles in HCC progression and reduced
miR-610 is correlated with Wnt/β-catenin signaling pathway.
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Hepatocellular carcinoma (HCC) is the fifth most pre-
valent cancer and the third leading cause of cancer mor-
tality worldwide [1-3]. Although the clinical course and
survival rates in HCC depend on the disease stage at
diagnosis, most patients are initially diagnosed at the* Correspondence: njiang163@163.com
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unless otherwise stated.advanced stages, there is no effective therapeutic treat-
ment, resulting in short survival time and poor prognosis
[4,5]. Poor understanding of the mechanisms underlying
HCC pathogenesis renders early-stage diagnosis and treat-
ment difficult [6]. Therefore, further studies are needed to
investigate the progression of HCC initiation and patho-
genesis, which would contribute to the exploration of
effective schemes for HCC diagnosis and therapy.
Wnt/β-catenin signaling pathway is highly conserved
in evolutionary processes and reported to be overactiva-
ted in the progresses of multiple tumors, including HCCtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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leads the abnormal activation of Wnt/β-catenin signaling
pathway correlated with cancers prognosis [11,14-16].
Satoshi et al. reported that β-catenin plays essential roles
in promoting HCC progression by stimulating HCC cell
proliferation and suppressing cell adhesion, and is asso-
ciated with a poor prognosis of HCC patients [14]. Fur-
thermore, Wnt/β-catenin signaling pathway modulates
multiple genes correlated with tumor progression, such
as Cyclin D, Ki67, and E-cadherein [14]. Therefore, it is
of great interest to investigate the regulatory mechanism
of Wnt/β-catenin signaling pathway in HCC and it might
be potential target for HCC diagnosis and therapy.
As a member of the expanding low-density lipoprotein
(LDL) receptor family, lipoprotein receptor-related pro-
tein 6 (LRP6), is found to be expressed in different types
of human tissues and LRP6 is one of Wnt-coreceptors,
which could activate the transcription of Wnt/β-catenin
target genes by promoting β-catenin translocation into
the nucleus [17-19]. Meanwhile, LRP6 is also found to
be correlated with cancer initiation and progression and
significantly overexpressed in various types of human
cancers, such as liver cancer, colon cancer, and kidney
tumor [20,21]. In HCC, LRP6 is also reported to be up-
regulated and overexpression of LRP6 enhanced HCC
cells proliferation, migration and invasion [22]. It has
been reported that transducin β–like protein 1 (TBL1X)
and its highly related family member TBLR1 could bind
to the E3 ubiquitin ligase components SIAH-1 and SKP1
to inhibit β-catenin degradation leading to the activa-
tion of Wnt/β-catenin signaling and TBL1-TBLR1and
β-catenin recruit each other to Wnt target-gene pro-
moter for transcription activation and oncogenesis [23].
Depletion of TBL1–TBLR1 inhibited Wnt-β-catenin-in-
duced gene expression and oncogenic growth [23,24].
Therefore, it would be interesting to investigate the
regulatory mechanism of LRP6 or TBL1X in HCC.
MicroRNAs (miRNAs), a class of small noncoding
RNAs, are important elements in numerous biological
activities and modulation of multiple cellular processes
through negative regulation of gene expression by tar-
geting the 3’ untranslated region (3’ UTR) of specific
mRNAs in a sequence-specific manner [25-27]. Aber-
rant miRNAs expressions have been implicated in the
initiation and progression of various tumors and plays
vital roles in tumor development [28-37].
In the present study, we reported that miR-610 was
downregulated in HCC cell lines and tissues. Inhibition
of miR-610 promoted, while upregulation of miR-610
suppressed, HCC cell proliferation and tumorigenicity
both in vitro and in vivo. Furthermore, we demonstrated
that miR-610 inhibited Wnt/β-catenin signaling activity
through directly downregulation of LRP6 and TBL1X.
Therefore, our results suggest that miR-610 might playimportant functions in HCC progression and represent a
potential target for HCC diagnosis and therapy.
Results
MiR-610 is downregulated in HCC and correlated with
progression and survival
By analyzing the published, microarray-based high-
throughput assessment (NCBI/GEO/GSE31384, n =166;
P <0.05), miR-610 was found to be significantly downreg-
ulated in HCC tissue compared with the matched non-
cancerous tissue (Additional file 1: Figure S1). To assess
whether miR-610 downregulation is linked to HCC pro-
gression, we analyzed miR-610 levels in 76 archived cli-
nical HCC specimens. As shown in Figure 1A, miR-610
levels remained high in grade I tumors but were markedly
lower in grade II, III and IV tumors. Statistical ana-
lysis revealed that miR-610 levels were inversely cor-
related with HCC progression (P <0.05; Additional file 2:
Table S1 and S2). Importantly, reduced miR-610 expres-
sion was closely associated with shorter overall survival
time (P <0.05) (Figure 1B, Additional file 2: Table S2).
Consistently, real-time PCR analysis revealed significant
downregulation of miR-610 expression in all seven HCC
cell lines compared with the two normal hepatic cell lines
(Figure 1C) and in the 10 HCC tissues compared with the
paired adjacent noncancerous tissues (Figure 1D). Collect-
ively, these results suggest that miR-610 is downregulated
in HCC and reduced miR-610 might represent as a pre-
dictive biomarker for HCC diagnosis and prognosis.
Inhibition of miR-610 enhances HCC cell proliferation and
cell cycle progression
To further explore the biological role of reduced miR-610
in HCC progression, MTT and colony formation assays
were performed and results of both assays revealed that
inhibition of miR-610 dramatically promoted prolifera-
tion of HCC cells compared with that of control cells
(Figure 2A and B, Additional file 3: Figure S2). Further-
more, BrdU incorporation assay showed that miR-610–
inhibited cells displayed higher DNA synthesis levels than
that in control cells (Figure 2C). Consistent with these
findings, cell cycle analysis using flow cytometry assay
showed a decreased percentage of G1/G0-phase cells and
an increased percentage of S-phase cells (Figure 2D).
These results indicate that miR-610 inhibition leads to the
promotion of HCC cell proliferation, which suggest that
miR-610 might function as a tumor suppressor.
Upregulation of miR-610 suppresses HCC cell proliferation
and cell cycle progression
We then determined whether miR-610 played tumor sup-
pressive role in HCC progression. As shown in Figure 3A,
cell viability, measured by MTT assay, was significantly
decreased in both miR-610-overexpressing HCC cell lines.
Figure 1 MiR-610 is downregulated in HCC and correlates with HCC progression and survival. A, Correlation between miR-610 expression
in different grades of HCC assessed by real-time PCR. Box boundaries represent lower and upper quartiles, respectively; lines within boxes and
whiskers denote median and extremum, respectively. B, Correlation between miR-610 levels and overall survival by Kaplan–Meier analysis of
patients with low (<median) or high (>median) miR-610 expression. C, MiR-610 expression levels in HCC cell lines compared with normal human
hepatic cells. D, Comparison of miR-610 levels in 10 paired HCC tissues (T) and their adjacent noncancerous tissues (ANT). Average miR-610
expression was normalized using U6 expression. Bars represent the means ± SD of three independent experiments. *P <0.05.
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significantly reduced the colony formation rate com-
pared with that in control cells (Figure 3B). Further-
more, DNA synthesis levels, as examined with the BrdU
incorporation assay, were significantly decreased in miR-
610-overexpressing HCC cells, whereas control cells had
relatively higher BrdU incorporation rates (Figure 3C).
Moreover, flow cytometry assay showed that miR-610-
overexpressing HCC cells exhibited significantly increased
percentage of G1/G0-phase cells and decreased per-
centage of S-phase cells (Figure 3D). Taken together,
these results suggest that miR-610 suppresses HCC cell
proliferation and cell cycle progression, which further
supports the notion that miR-610 might be a tumor-
suppressive miRNA.
MiR-610 suppresses HCC cell tumorigenicity both in vitro
and in vivo
To examine the effect of miR-610 on HCC cell tumorigen-
icity, we established HCC cell lines, which stably expressed
or inhibited miR-610, and performed an anchorage-
independent growth assay (Additional file 4: Figure S3,
Additional file 5: Figure S4A-B). The result showed that
the HCC cells stably expressing miR-610 formed fewerand smaller colonies than the control cells did, while
miR-610 inhibition using a stable miRNA sponge led to
formation of more and larger colonies. We further ex-
amined miR-610 biofunction in suppression of HCC
cell tumorigenicity in vivo by inoculating nude mice
with tumor cells. The volume and weight of miR-610–
overexpressing tumors were markedly lower compared
with the tumors formed by control cells, indicating the
suppressive function of miR-610 on HCC cell tumori-
genicity in vivo (Figure 4C–E). Consistently, inhibition
of miR-610, using the stable miRNA sponge strategy,
drastically enhanced HCC cell tumorigenicity in vivo,
for which tumor sizes were much larger (Figure 4C–E).
Our results demonstrate that miR-610 could suppress
HCC cell tumorigenicity both in vitro and in vivo.
LRP6 and TBL1X are functionally relevant downstream
targets of miR-610
The TargetScan algorithm indicated that LRP6 and
TBL1X, which might be targets of miR-610 (Figure 5A).
Western blotting analysis revealed that LRP6 and TBL1X
expression were significant downregulated in miR-610-
overexpressing cells but upregulated in miR-610-inhibited
cells, while we did not observed significant alterations of
Figure 2 MiR-610 inhibition enhances HCC cell proliferation and cell cycle progression. A, MTT analysis of cell growth rates of cell lines
transfected with miR-610 inhibitor (miR-610-in) or negative control (NC) after seeding. B, Representative micrographs (left) and quantification
(right) of HCC cell colonies determined by colony formation assay. C, Representative micrographs (left) and quantification (right) of BrdU
incorporation in HCC cells. D, Flow cytometry analysis of cell cycle progression in HCC cells. Bars represent the means ± SD of three independent
experiments. *P <0.05.
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Figure S4). To confirm whether LRP6 and TBL1X were
direct targets of miR-610, luciferase reporter vector
containing the 3’ UTR fragment of the LRP6 or TBL1X
gene was co-transfected with either miR-610 mimic or
miR-610 inhibitor into HCC cells. As shown in Figure 5C,
ectopic expression of miR-610 decreased, while inhi-
bition of miR-610 increased, the luciferase activity of
either the LRP6 or TBL1X 3’ UTR, but not the LRP6 or
TBL1X 3’ UTR with mutant binding cites. Moreover,the miR-610 mutant also failed to show an inhibitory
effect on the luciferase expression of either the LRP6 or
TBL1X 3’ UTR (Additional file 6: Figure S5A and B).
Moreover, miRNPs immunoprecipitation assay revealed
a selective association of miR-610 with LRP6 or TBL1X,
but not with GAPDH (Additional file 6: Figure S5C
and D), indicating that miR-610 negatively regulated
these proteins via directly binding to their 3’UTRs. These
results suggest that LRP6 and TBL1X are direct down-
stream targets of miR-610.
Figure 3 Ectopic miR-610 expression inhibits HCC cell proliferation and cell cycle progression. A, MTT analysis of cell growth rates of
indicated cell lines after seeding. B, Representative micrographs (left) and quantification (right) of HCC cell colonies determined by colony
formation assay. C, Representative micrographs (left) and quantification (right) of BrdU incorporation in HCC cells. D, Flow cytometry analysis of
cell cycle progression in HCC cells. Bars represent the means ± SD of three independent experiments. *P <0.05. NC, negative control.
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signaling
As both TBL1X and LRP6 were demonstrated to play
important roles in activation of Wnt/β-catenin pathway
[18,19,24,25], therefore, we further examined whether
miR-610 was involved in the regulation of Wnt/β-catenin
signaling. As shown in Figure 6A, the β-catenin reporter
assay revealed that ectopic miR-610 remarkably decreased,
while miR-610 inhibitor increased, the TCF/LEF activities
in both BEL-7404 and HCCC-9810 cells. Consistently,immunofluorescence staining showed ectopic miR-610
led to significant cytoplasm location of β-catenin, whereas
inhibition of miR-610 resulted in stronger nuclear signals
of β-catenin (Figure 6B). In addition, the subcellular frac-
tionation assay showed a significant nuclear accumulation
of β-catenin in miR-610-inhibited BEL-7404 and HCCC-
9810 HCC cell lines, whereas miR-610-overexpressed
HCC cells displayed dramatically decreased β-catenin in
nucleus (Figure 6C). Meanwhile, we found that the down-
stream target genes of Wnt/β-catenin signaling, including
Figure 4 MiR-610 suppresses HCC cell tumorigenicity both in vitro and in vivo. A and B, Representative micrographs (left) and quantification
(right) of colony formation determined by anchorage-independent growth assay in vitro. Colonies >0.1 mm were scored. C, Average tumor volumes
(mm3) of different treatment groups after inoculation. D, Representative images of tumors in the different treatment groups. E, Analysis of weight
of subcutaneous tumors from the different treatment groups. Bars represent the means ± SD of three independent experiments. *P <0.05.
NC, negative control.
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were downregulated in cells transfected with miR-610
mimic and upregulated in cells transfected with miR-610
inhibitor (Figure 6D). Moreover, western blotting revealed
that expression levels of phosphorylated β-catenin was
dramatically increased in miR-610-overexpressing cells
and decreased in miR-610-inhibited cells. Consistently,
the expression of Cyclin D1 and c-Myc were suppressed
by ectopic miR-610 expression and upregulated by miR-
610 inhibition (Figure 6E). Taken together, these data
suggest that downregulation of miR-610 activates Wnt/
β-catenin signaling and promotes TCF/LEF transcrip-
tional activity.
Consistently, we also found that inhibition of miR-610
function by miR-610-sponge suppressed the expression
of LRP6 and TBL1X, accompanied with the high level of
nuclear expression of β-catenin, in the xenograft tumors.
However, overexoressing miR-610 resulted in the upregu-
lation of LRP6 and TBL1X and reduced nuclear β-catenin
in the xenograft tumors (Additional file 7: Figure S6).
These data further confirm that miR-610 suppresses HCC
cell tumorigenicity by inhibit the activity of β-catenin via
targeting LRP6 and TBL1X.Wnt/β-catenin signaling mediates miR-610-mediated HCC
proliferation
Next, the critical role of LRP6 and TBL1X in miR-610-
inhibiting HCC cell proliferation was examined. As
shown in Figure 7A-B, individual silencing of LRP6 or
TBL1X potently inhibited TCF/LEF activity in miR-610
silenced cells, demonstrating that LRP6 and TBL1X are
functional effectors of reduced miR-610-regulated Wnt/
β-catenin activation. Inhibition of Wnt/β-catenin signal-
ing by silencing LRP6 or TBL1X prevented the pro-
moted miR-610-inhibitor-induced proliferative rates and
the anchorage-independent growth ability (Figure 7C
and D), as well as the expression of Cyclin D1 and c-Myc
(Figure 7E), suggesting that LRP6 and TBL1X involved
in miR-610 inhibiton-induced proliferation and tumori-
genicity of HCC cells.
Furthermore, the critical role of Wnt/β-catenin signal-
ing in miR-610-mediated HCC cell proliferation was ex-
plored. We analyzed the growth rate of miR-610-inhibited
HCC cells in which the Wnt/β-catenin signaling was sup-
pressed with TCF4-siRNA or LEF1-siRNA (Additional
file 8: Figure S7A and B). Consistent with silencing
LRP6 or TBL1X, inhibition of Wnt/β-catenin signaling
Figure 5 LRP6 and TBL1X are direct targets of miR-610. A, Schematic representation of mature miR-610 sequence and miR-610 target sites in
the 3’ UTRs of the LRP6 and TBL1X mRNAs. B, Western blot analysis of LRP6 and TBL1X expression in HCC cells transfected with miR-610 mimic,
inhibitor (miR-610-in) or negative control (NC); α-tubulin was used as the loading control. C, Luciferase assay of pGL3-LRP6-3’UTR or pGL3-TBL1X-
3’UTR reporter cotransfected with miR-610 mimic or inhibitor in HCC cells. Bars represent the means ± SD of three independent experiments.
*P <0.05. Hsa, Homo sapiens.
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of Cyclin D1 and c-Myc, the silenced miR-610-induced
proliferative rates and the anchorage-independent growth
ability (Additional file 8: Figure S7C-E), further suggesting
that Wnt/β-catenin signaling played important role in the
bio-function of miR-610 in HCC cells.
Clinical relevance of miR-610 reduction-mediates
Wnt/β-catenin activation in HCC
Finally, we examined whether miR-610 downregulation-
mediated Wnt/β-catenin signaling activation in HCC
cells was clinically relevant. As shown in Figure 8, miR-610
expression in 10 freshly collected HCC samples was in-
versely correlated with the mRNA levels of Wnt/β-catenin
downstream targets, including Cyclin D1 (r = -0.842,
P = 0.01), MYC (r = -0.804, P = 0.03), as well as ex-
pression of LRP6 (r = -0.805, P = 0.006) and TBL1X
(r = -0.835, P = 0.024). Collectively, our results demon-
strate that miR-610 downregulation activates Wnt/β-
catenin signaling, resulting in HCC tumorigenicity and
poorer clinical outcomes.Discussion
More than 80% of all HCC cases occur in developing
countries, and approximately 55% of all cases occur in
China, particularly in the southeast regions [38]. There-
fore, discovery of effective diagnostic biomarkers and
therapeutic methods is urgent. An increasing number of
studies have shown that miRNAs may be significant diag-
nostic and prognostic markers [6,35-37]. In the current
study, we found that miR-610 was downregulated in HCC
tissue and reduced miR-610 levels were significantly cor-
related with HCC progression and poor patient survival,
suggesting that reduced miR-610 might play essential roles
in HCC progression and represent a potential target for
HCC therapy.
Numerous-reports demonstrated that the Wnt/β-
catenin signaling pathway plays important roles in the
progression of various human cancer types via modula-
tion of many biological processes, including cell growth,
invasion and metastasis, apoptosis, differentiation and
stem cell development [39-42]. Herein, we demonstra-
ted that miR-610 suppressed HCC cell proliferation and
Figure 6 (See legend on next page.)
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Figure 6 MiR-610 suppresses β-catenin signaling pathway activity. A, Luciferase assay of TCF/LEF transcriptional activity in indicated cells
transfected with miR-610 mimic or inhibitor (miR-610-in). B, The cellular location of β-catenin in indicated HCC cells, as determined by
immunofluorescence staining (with magnification × 1000). C, The expression (upper) and quantification (lower) of cytoplasm and nuclear
β-catenin in indicated HCC cell lines, determined by Western blot; β-actin was used as the cytoplasm protein marker, and p84 as the nuclear
protein marker. D, Real-time PCR analysis of mRNA expression of CCND1, MYC, AXIN2, LEF1, JUN and FGF4 genes in HCC cells. E, Western blot
measurement of phosphorylated β-catenin (p-β-catenin), β-catenin, CCND1 and c-Myc expression in HCC cells; α-tubulin was used as the loading
control. Bars represent the means ± SD of three independent experiments. *P <0.05. NC, negative control.
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the Wnt/β-catenin signaling pathway. Previously, it has re-
ported that multiple downstream target genes of Wnt/
β-catenin pathway were increased in various malignan-
cies, which were correlated with tumor progression and
prognosis [8,9,14,43]. We examined the expression of
the main downstream target genes of the β-catenin sig-
naling pathway, i.e. CCND1, MYC, AXIN2, LEF1, JUN,Figure 7 Wnt/β-catenin signaling mediated miR-610-mediated HCC p
miR-610-inhibited HCC cells transfected with LRP6-siRNA or TBL1X-siRNA. B
C, Quantification of indicated HCC cell colonies determined by colony form
anchorage-independent growth assay. E, Real-time PCR analysis of mRNA e
independent experiments. *P <0.05.FGF4 and MMP7, and found that ectopic miR-610 de-
creased the mRNA expression of these genes, sugges-
ting miR-610 modulates β-catenin signaling pathway.
As Wnt/β-catenin signaling pathway regulates a series
of genes related to biological progression in various tu-
mors, it would be interesting to further investigate whe-
ther miR-610 also contributes to the aggressiveness of
HCC, such as invasion and metastasis.roliferation. A, Western blot analysis of LRP6 and TBL1X expression in
, Luciferase assay of TCF/LEF transcriptional activity in indicated cells.
ation assay. D, Quantification of colony formation determined by
xpression of CCND1 and MYC. Bars represent the means ± SD of three
Figure 8 The expression of miR-610, and Wnt/β-catenin signaling related genes in HCC tissues. A, Real-time PCR analysis of miR-610, Cyclin
D1, MYC, and Western blot analysis of LRP6 and TBL1X expression in HCC tissues. B, The correlation between miR-610 expression and LRP6 and
TBL1X, or Cyclin D1 and MYC expression in HCC tissues. Error bars represent the mean ± SD from three independent experiments.
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that cannot be successfully treated by targeting a single
gene of interest, therefore understanding of the regula-
tory networks of many molecules will aid the exploration
of effective therapeutic methods. It has been reported
that miR-21 is involved in glioblastoma progression and
is recognized as an anti-apoptotic factor due to its ability
to block the genes responsible for controlling apoptosis
[44]. MiR-486 overexpression correlates with progression
of gliomas and promotes glioma aggressiveness by sustain-
ing nuclear factor κB (NF-κB) activity via disrupting mul-
tiple NF-κB negative feedback loops [45]. miRNA-374a
promotes breast cancer metastasis by downregulating
WIF1, PTEN and WNT5A expression, consequently ac-
tivating WNT/β-catenin signaling [46]. Our study sug-
gests that miR-610 inhibits HCC cell proliferation and
tumorigenesis through direct and specific regulation of
LRP6 and TBL1X, which have been demonstrated to
acted as positive regulators of the β-catenin signaling
pathway. The results provide more information for es-
tablishing effective and promising therapeutic strategies
aiming at miRNA-modulating networks.
Both LRP6 and TBL1X are found to function as onco-
genes during tumor progression [18,23,47]. LRP6 is foundto be targeted and suppressed by miR-126-3p leading to
inhibition of tumor metastasis and angiogenesis of hepa-
tocellular carcinoma [48]. Zhang Y et al. found that miR-
202 suppresses cell proliferation in human hepatocellular
carcinoma by downregulating LRP6 protein expression
[49]. Meanwhile, it has been reported that miR-483-5p
modulates the protein level of TBL1X, which is one of the
Methyl CpG-binding protein 2 (MeCP2)-interacting core-
pressor complexes during human fetal development [50].
In the current study, we found LRP6 and TBL1X are tar-
geted by miR-610, and overexpression of miR-610 could
inhibit proliferation and tumorigenesis of HCC cells by
suppressing the expression of LRP6 and TBL1X, followed
by downregulation of β-catenin signaling activity.
MiR-610 locates at chromosome 11p14.1. The region
11p14.1 deletion was found to be associated with mul-
tiple disease, such as Attention-Deficit Hyperactivity
Disorder (ADHD), autism, developmental delay, obesity,
neurobehavioral problems and WAGR syndrome (Wilms
tumor, aniridia, genitourinary anomalies, and mental re-
tardation) [51,52]. Therefore, it would be of great interest
to further investigate whether reduced miR-610 in HCC is
attributed to genomic deletion and/or other transcrip-
tional regulation mechanism.
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In summary, we observed that miR-610 expression was
reduced in HCC cells and tissues, which was correlated
with HCC progression and survival. Consistently, miR-
610 overexpression inhibited HCC cell proliferation and
tumorigenicity, while miR-610 inhibition enhanced cell
growth and tumor formation. Furthermore, we demon-
strated that miR-610 directly suppressed LRP6 and
TBL1X, which resulted in activation of WNT/β-catenin
signaling activity. Our findings reveal novel roles for
miR-610 in HCC development and progression and
suggest miR-610 as a potential target for HCC diagno-
sis and treatment.Methods
Cell culture
The immortalized normal liver epithelial cell lines THLE-
3 and LO2 were purchased from American Type Culture
Collection (Manassas, VA, USA) and cultured according
to the manufacturer’s instructions. HCC cell lines (HepG2,
BEL-7404, Huh7, BEL-7402, PLC/PRF, Hep3B, HCCC-
9810) were purchased from American Type Culture Col-
lection and maintained in RPMI 1640 medium (Invitrogen,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (FBS, Invitrogen) at 37°C in a 5% CO2 incubator.Generation of stably engineered cell lines
The miR-610 expression plasmid pMSCV-miR-610 was
generated by cloning the genomic precursor miR-610 gene
into a retroviral transfer plasmid pMSCVpuro (Promega,
Madison, WI, USA). pMSCV-miR-610 was then cotrans-
fected with the packaging plasmid into 293FT cells using
the standard calcium phosphate transfection method [53].
Puromycin (0.5 μg/ml, Sigma-Aldrich) was used to select
stably transduced cells. Real-time quantitative polymerase
chain reaction (PCR) was used to confirm miR-610 ex-
pression. MiR-610 mimic, inhibitor and negative control
were purchased from RiboBio (Guangzhou, China). Oligo-
nucleotide transfection was performed using Lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s
instructions.Tissue specimens and patient information
We examined 76 paraffin-embedded, archived HCC spe-
cimens and 10 pairs of snap-frozen HCC tumors and
matched adjacent normal tissues that had been histo-
pathologically diagnosed and verified by experienced pa-
thologists. The fresh tissues were frozen and stored in
liquid nitrogen until further use. Prior patient consent
and approval from the Institute Research Ethics Com-
mittee were obtained for the use of clinical materials for
research purposes.RNA extraction and real-time quantitative PCR
Total cellular RNA was extracted using TRIzol (Invitrogen)
according to the manufacturer instructions. Reverse tran-
scription was performed using the M-MLV Reverse Tran-
scription system (Promega). Real-time PCR was performed
using a standard SYBR Green PCR kit protocol (Applied
Biosystems, Foster City, CA) in an ABI PRISM 7500 Se-
quence Detection System (Applied Biosystems). Gene ex-
pression levels were normalized to the housekeeping gene
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as
the control and calculated as 2-[(Target gene Ct) – (GAPDH Ct)],
where Ct represents the threshold cycle for each tran-
script. The relative expression levels were calculated as
2-[(miR-610 Ct) – (U6 Ct)] following normalization with ref-
erence to the expression of small nuclear RNA U6.
The primers used were: LRP6 forward, 5′-TCAGTC
CATTT GGCCAGTAA-3′, reverse: 5′-CAACCCAGAG
CTATTGCCTT-3′; TBL1X forward, 5′-CAGGGCTC
CTTATGGTG ACT -3′, reverse: 5′- CATATCAGATG
CCTCGCAGA -3′;cyclin D1 (CCND1) forward, 5′-AA
CTACCTGGACCGCTTCCT-3′, reverse: 5′-CCACTTG
AGCTT GTTCACCA-3′; MYC forward: 5′-TCAAGA
GGC GAACACACAAC-3′, reverse: 5′-GGCCTTTTCA
TTGTTTTC CA-3′; AXIN2 forward: 5′-TTATGCTT
TGCACTACGTCC CTCCA-3′, reverse: 5′-CGCAAC
ATGGTCAAC CCTCAGAC-3′; lymphoid enhancer -
binding factor 1 (LEF1) forward: 5′-CACTGTA AGTGA
TGAGGGGG-3′, reverse: 5′-TGGATCTCTTTCTCCA
CCCA-3′; JUN forward: 5′-CAGGTGGCACAGCTTA
AACA-3′, reverse: 5′-GTTTGCAACTGCTGCGTTA
G-3′; fibroblast growth factor 4 (FGF4) forward: 5′-
CGTGGTGAGCATCTTCGGAGTGG-3′, reverse: 5′-CC
TTCTTGGTCCGCCCGTTC TTA-3′; matrix metallo-
proteinase 7 (MMP7) forward: 5′-GTATGGGACATTCC
TCTGAT CC-3′, reverse:5′-CCAATGAATGAATGAAT
GG ATG-3′; GAPDH forward: 5′-GACTCAT GACCAC
AGTCCATGC-3′, reverse: 3′-AGAGGCAGGGATGATG
TTCTG-5′. The primers used for miR-610 and U6 stem–
loop reverse transcription–PCR were purchased from
RiboBio.
Western blotting
Cells were lysed in 1× sample buffer and protein concen-
trations were measured using Bio-Rad protein assay re-
agent (Bio-Rad Laboratories, Berkeley, CA, USA). Protein
(20 μg) was separated by electrophoresis and transferred
onto polyvinylidene difluoride membranes (Millipore,
Billerica, MA, USA). The membranes were probed with
polyclonal rabbit antibodies, anti-LRP6 (Cell Signaling,
Danvers, MA, USA), anti-TBL1X (Sigma-Aldrich), anti-β-
catenin, anti-phospho-β-catenin, anti-CCND1 and anti-c-
Myc (Cell Signaling). The membranes were then stripped
and re-probed; an anti-α-tubulin antibody (Cell Signaling)
was used as a loading control.
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Cell viability was measured by MTT assay. Cells (1 × 104)
were cultured in 96-well plates and stained at the indi-
cated time points with 100 μl sterile MTT (0.5 mg/ml;
Invitrogen) for 4 h at 37°C, followed by removal of the cul-
ture medium and the addition of 150 μl dimethyl sulfoxide
(Sigma-Aldrich), followed by measurement of the absorb-
ance at 570 mm. Relative cell numbers were calculated in
sextuplicate in three independent experiments.
Colony formation assay
Cells were trypsinized and seeded in 6-well plates (1 × 103
cells per well). After 10 days, cells were fixed with 10% for-
maldehyde for 15 min, stained with 1.0% crystal violet for
5 min, and then counted and photographed. All experi-
ments were performed in triplicate.
BrdU incorporation assay
The level of DNA synthesis was determined by estimat-
ing DNA uptake of 5-bromo-2’-deoxyuridine-5’-mono-
phosphate (BrdU). Cells were trypsinized, transferred to
a sterile coverslip and allowed to settle. After 48-h se-
rum starvation and 4 h incubation in complete medium,
cells were fixed and permeabilized with 0.1% Triton for
10 min. Subsequently, cells were labeled with BrdU
(10 μM; Sigma-Aldrich) for 1 h, incubated in serum-free
medium containing anti-BrdU antibody for 1 h at 37°C
and incubated with 4’, 6-diamidino-2-phenylindole for
nuclear staining. Each experiment was repeated three
times independently; stained cells were counted under a
fluorescence microscope (Olympus, Tokyo, Japan).
Flow cytometry analysis
Cells were harvested by trypsinization and fixed in 80%
ice-cold ethanol in phosphate-buffered saline. Bovine
pancreatic RNase (2 μg/ml; Sigma-Aldrich) was added to
the cells, followed by 30-min incubation at 37°C, and
then 30-min incubation in propidium iodide (10 μg/ml,
Invitrogen) at room temperature. Propidium iodide–stained
cells (>10,000 cells) were analyzed using a FACSCalibur
flow cytometer (BD Biosciences, San Jose, CA, USA). All
experiments were performed in triplicate.
Anchorage-independent growth assay
RPMI 1640 medium (1.5 ml) containing 10% FBS and
0.33% agar was plated in 6-well plates that were stored
at 4°C for the agar to solidify. The cells were trypsinized
and 1 × 103 cells per well were mixed with RPMI 1640
medium containing 10% FBS and 0.66% agar and plated
on the prepared 6-well plates. After 10-day incubation,
colony sizes were measured using an ocular micrometer;
colonies >0.1 mm in diameter were scored. All experi-
ments were performed in triplicate.Xenograft tumors
We used 5-week-old BALB/c nude mice for the HCC
xenograft model. Medium (0.2 ml) containing 5 × 106
HCC cells were injected subcutaneously into the left and
right posterior flank regions of each mouse. Mice were
housed in a pathogen-free environment and tumor growth
was examined every three days. Mice were sacrificed after
21 days, and the weight and volume of each tumor were
calculated. All experimental procedures were conducted
in accordance with the Guide for the Care and Use of
Laboratory Animals and conformed to our institutional
ethical guidelines for animal experiments.
Luciferase assay
The 3’ UTR of the LRP6 or TBL1X gene was PCR-
amplified from genomic DNA and inserted downstream
of the luciferase reporter gene in a pGL3 reporter vector
(Promega). The primer sets used were: 3’-UTR of LRP6
containing the miR-610 binding site, 5′- AATCCGCGG
GG GTTGTATTTCTTTATCATT -3′ and 5′- GCCCT
GCAG CGCATACCTCTTCAGTCTC -3′; 3′-UTR of
TBL1X containing the miR-610 binding site, 5′- AATC
CGCGGTGTCTTGGG CTTGTTGTC -3′ and 5′- GC
CCTGCATCTGTGGC TTC TTCGGTTC -3′. LRP6-3′
UTR mutant: 5′- AGCTCCATTCCCCAGTAGGCTT
AGGAGTTC AATTTGACT GCTGTTTTTGC-3′ and
5′- CAGCAGTCAAATTGAACTCCTAAGCCTA CTG
GGGAATGGAGCT-3′; TBL1X-3’UTR mutant: 5′- AT
CACCTTGTGTGTTGTAG GAGA TTTGTTTCAAGA
GAGAATCAACAGATC-3′ and 5′- GATCTGTTGAT
TCTCT CTTGAAA CAAATCTCCTACAACACACAA
GGTGAT-3′. Reporter plasmids containing wild-type
(CCTTTGATC; TOPflash) or mutated (CCTTTGGCC;
FOPflash) T cell factor (TCF)/LEF DNA binding sites
were purchased from Upstate Biotechnology (Lake Placid,
NY, USA). Cells were plated in a 24-well plate and incu-
bated for 24 h prior to transfection. Firefly luciferase con-
structs containing the 3’ UTR of the potential miR-610
target, pRL-TK Renilla luciferase normalization control
(Promega), miRNA mimic, inhibitor or negative control
were cotransfected using Lipofectamine 2000 (Invitrogen).
Lysates were collected 48 h after transfection and mea-
sured using a Dual-Luciferase Reporter System (Promega)
according to the manufacturer protocol. Three independ-
ent experiments were performed and the data presented
as the means ± SD.
Nuclear protein extraction assay
The nuclear protein extraction assay was conducted using
Nuclear Extraction Kit (Life Technologies, Carlsbad, CA,
USA). Briefly, Collect cells (5 × 106) were collected and
washed by cold PBS, and gently resuspended with 500 μl
1× Hypotonic Buffer, followed by incubating on ice for
15 minutes. Add 25 μl detergent (10% NP40) and vortex
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ate for 10 minutes at 3,000 rpm at 4°C. Transfer and save
the supernatant. This supernatant contains the cytoplas-
mic fraction. The pellet is the nuclear fraction. Resuspend
nuclear pellet in 50 μl complete Cell Extraction Buffer for
30 minutes on ice with vortexing at 10 minute intervals.
Centrifuge for 30 minutes at 14,000 g at 4°C. Transfer
supernatant (nuclear fraction) to a clean microcentrifuge
tube. The nuclear extracts are ready for assay.
Micro-ribonucleoprotein complex immunoprecipitation
assay
Cells were cotransfected with a plasmid encoding
hemagglutinin–argonaute 1 (HA-Ago1 or -Ago2) (Addgene,
Cambridge, MA, USA) and miR-610 mimic (100 nM),
followed by HA-Ago1 or -Ago2 immunoprecipitation
(IP) using an anti-HA antibody (Roche Applied Science,
Mannheim, Germany). The association of the LRP6 and
TBL1X mRNA with the RNA-induced silencing com-
plex was tested using real-time PCR analysis of the IP
product. The primers used: LRP6, 5′- CGACTTGAA
CCATCCATTCC-3′ and 5′- CAACCCAGAGCTATT
GCCTT-3′; TBL1X, 5′- TGTATG GACCTGTGGAC
CAG-3′ and 5′- CATATCAGATGCCTCGCAGA-3′.
Statistical analysis
All statistical analyses were performed using SPSS soft-
ware. The association between miRNA expression and
tumor stage was assessed using the Fisher exact test or
Pearson χ2 test. We used the Kaplan–Meier method to
estimate survival; log-rank testing was used to test dif-
ferences between survival curves. Data are reported as
means ± SD; mean values were compared using Student’s
t-test. Results were considered statistically significant
when P <0.05.
Additional files
Additional file 1: Figure S1. Analysis of miR-610 expression in a
published, microarray-based high-throughput assessment (NCBI/GEO/
GSE31384, n =166, P <0.05).
Additional file 2: Table S1. Clinicopathological characteristics of
studied patients and expression of miR-610 in HCC. Table S2. Correlation
between the clinicopathological features and expression of miR-610.
Additional file 3: Figure S2. Ectopic miR-610 expression inhibits HCC
cell HepG2 and Hep3B proliferation and colony formation. A, MTT analysis
of cell growth rates of indicated cell lines after seeding. B, Representative
micrographs (left) and quantification (right) of HCC cell colonies determined
by colony formation assay. Bars represent the means ± SD of three
independent experiments. *P <0.05. NC, negative control.
Additional file 4: Figure S3. The expression of miR-610 in xenograft
tumors, determined by Real-time PCR. Average miR-610 expression was
normalized using U6 expression. Bars represent the means ± SD of three
independent experiments. *P <0.05.
Additional file 5: Figure S4. The expression of LRP6 and TBL1X mRNA
in indicated cells, determined by Real-time PCR. Average mRNA expressionwas normalized using GAPDH expression. Bars represent the means ± SD of
three independent experiments. P >0.05.
Additional file 6: Figure S5. LRP6 and TBL1X are direct targets of
miR-610. A, Schematic representation of mutant miR-610 sequence and
miR-610 target sites in the 3’ UTRs of the LRP6 and TBL1X mRNAs. B,
Luciferase assay of pGL3-LRP6-3’UTR or pGL3-TBL1X-3’UTR reporter
cotransfected with miR-610 mimic or miR-610-mut in HCC cells. C and D,
MiRNP IP assay revealing the association between miR-610 and LRP6 or
TBL1X. MiRNP IP assay was conducted using AGO1 (C) and AGO2 (D)
plasmid. Bars represent the means ± SD of three independent experiments.
*P <0.05.
Additional file 7: Figure S6. The expression of LRP6, TBL1X and
β-catenin in xenograft tumors, determined by immunohistochemistry.
Additional file 8: Figure S7. Wnt/β-catenin signaling mediated
miR-610-mediated HCC proliferation. (A) Western blot analysis of TCF4
and LEF1 expression in miR-610-inhibited HCC cells transfected with
TCF4-siRNA or LEF1-siRNA. (B) Luciferase assay of TCF/LEF transcriptional
activity in indicated cells. (C) Real-time PCR analysis of mRNA expression
of CCND1 and MYC. (D) Quantification of indicated HCC cell colonies
determined by colony formation assay. (E) Quantification of colony
formation determined by anchorage-independent growth assay. Bars
represent the means ± SD of three independent experiments. *P <0.05.
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